Attached for release to the market is a copy of the presentation to be delivered today by Phosphagenics Limited at the Australian Life Science Investment Showcase in New York hosted by AusBiotech (supported by Ernst & Young and the Australian Government).

-ENDS-

For further information, please contact

David Segal
Investor Relations Manager
Phosphagenics Limited
+61 3 9565 1103

**About Phosphagenics**
Phosphagenics is commercialising drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® – Targeted Penetration Matrix technology. TPM® is a patient friendly and cost effective system used to deliver proven pharmaceutical and nutraceutical products.

The lead product advancing through clinical trials is an oxycodone matrix system for the relief of chronic pain.

Phosphagenics’ shares are listed on the Australian Securities Exchange (POH) and its ADR – Level 1 program in the US is with The Bank of New York Mellon (PPGNY).

[www.phosphagenics.com](http://www.phosphagenics.com)
This presentation contains forward-looking statements based on current expectations of future events. If underlying assumptions prove inaccurate, or unknown risks or uncertainties materialize, actual results could vary materially from Phosphagenics’ expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations.
Phosphagenics Ltd is an ASX-listed life sciences company in the early-mid stages of commercializing drug delivery applications based on its novel transdermal (drugs administered via skin) TPM® - Targeted Penetration Matrix - technology.

Company Overview

**Board & Management**

Jonathan Addison (Chairman & Independent Director)
Harry Rosen (President & Founder)
Dr Esra Ogru (Chief Executive Officer)
Donald Clarke (Independent Director)
Stuart James (Independent Director)
Sandra Webb (Independent Director)

**Key Statistics**

- **ASX Code**: POH
- **Market capitalization**: $163 million (as at 06/06/12)
- **Share price – current/52 wk High – 52 wk low**: 16 cents / 24.5 - 9.7 cents
- **Cash**: $27 million (as at 12/31/11)
- **Employees**: 35-40

**Share Price Performance**

**Major Shareholders**

- **Institutions**: 38%
- **Retail shareholders**: 28%
- **Large private sophisticated**: 14%
- **Founding Shareholders & Staff**: 20%
Strong Financial Position

- Company now strongly funded
- October 2011 capital raising
  - $27.1m capital successfully raised in October 2011
  - Institutional share placement and share purchase plan heavily oversubscribed
- Sufficient funds to steer our lead pharmaceutical program – TPM®/Oxycodone – through pivotal trails
- Funding positions the company to exploit TPM® technology
- Strengthened our commercial and business development team
TPM® Technology Overview

- Phosphagenics is a world-leader in transdermal drug delivery technology: TPM® – “Targeted Penetration Matrix”
- TPM® is comprised of two active components derived from Vitamin E: mono-tocopheryl and di-tocopheryl phosphate
- TPM® is manufactured at Phosphagenics’ Melbourne plant and is protected by a robust IP portfolio of 20 patent families
- TPM® has applications both as a delivery system and as an active across multiple products and markets
- TPM® as a platform delivery system
  - is a multi-functional and multi-component delivery system
  - has proven capacity to deliver small and large molecules
  - is a non-invasive and non-irritant delivery system
Key Current Projects

<table>
<thead>
<tr>
<th>Category</th>
<th>Projects/Therapies</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>PAIN</strong></td>
<td>Oxycodone (3M; Labtec)</td>
</tr>
<tr>
<td></td>
<td>Systemic delivery</td>
</tr>
<tr>
<td></td>
<td>Topical delivery</td>
</tr>
<tr>
<td></td>
<td>Diclofenac (global partner; Themis; Nippon Zoki)</td>
</tr>
<tr>
<td><strong>DERMATOLOGY</strong></td>
<td>Anti-acne therapies (global partner)</td>
</tr>
<tr>
<td><strong>ANIMAL HEALTH</strong></td>
<td>Mastitis - cattle (Mastitis Management Aus)</td>
</tr>
<tr>
<td></td>
<td>Insulin - pets (Novartis)</td>
</tr>
<tr>
<td><strong>PERSONAL CARE</strong></td>
<td>Elixia®/BioElixia™ (own brand)</td>
</tr>
<tr>
<td></td>
<td>Le Metier de Beaute® (licensed brand)</td>
</tr>
<tr>
<td></td>
<td>Mass market (global partner; US partner)</td>
</tr>
</tbody>
</table>

TPM® as a delivery system
TPM® significantly improves the delivery of a range of pharmaceutical and dermatological actives into the skin (topical) or the blood (systemic).

Unlike all other penetration enhancement systems and vesicular systems, TPM® can be modulated to control the rate and location of delivery, and can be modified to enhance compatibility with molecules of widely different chemistries.

TPM® can be formulated into a gel, patch or spray system offering various dosage forms to suit specific indications, with proven delivery of: TPM®/Insulin; TPM®/Oxycodone; TPM®/Morphine; TPM®/NSAIDs; TPM®/Atropine.
Pharmaceutical Applications TPM®/oxycodone

- TPM®/oxycodone: world’s first oxycodone patch
- Potential blockbuster product for chronic pain
- Multi-billion dollar global market – $3.5 billion p.a.
- Survey indicates projected peak sales – $1 billion p.a.
- Reproducible, non-invasive delivery using TPM®
- Global development partners 3M and Labtec
- Internationally recognized advisory board
Advantages of TPM®/oxycodone

- The most common disadvantages of oral oxycodone usage:
  - GI-related side effects such as constipation, head-aches, dizziness
  - Short duration of effect; breakthrough pain can occur within 6-8 hours
  - Development of tolerance thereby requiring increased dosage over time
  - Rapid absorption creates euphoria; the incentive for drug abuse
  - Oxycodone can be readily extracted for secondary market abuse
  - Certain patient populations are unable to swallow pills

- Transdermal delivery through TPM®/oxycodone addresses ALL these serious issues

- The TPM®/oxycodone patch has produced successful results in Phase I trials; Phase III trials are expected to commence 1st quarter 2013
Creating Value….Strong Pharma Partnerships

• Creating value by leveraging TPM® technology across diverse markets

• Developing global strategic alliances in the fields of anti-acne therapy, topical diclofenac (NSAID), animal health products and large molecule delivery (ie insulin)

• Our partnerships provide:
  – Synergistic path to value
  – Credibility
  – Financial and technical support
  – Risk reduction through diversification
  – Commercialization pathway

PHOSPHAGENICS
• TPM’s unique properties make it ideal for use in personal care as a delivery system

• **TPM® as a delivery system:**
  
  – **Prestige market:** TPM® is licensed to US cosmetics company Le Métier de Beauté for use in several anti-aging products sold into high-end US department stores.

  – **Mid-market:** TPM® is used in Phosphagenics’ own brands – Elixia® (in Australia) and BioElixia™ (ex Australia) – to deliver select anti-aging and anti-cellulite actives.

  – **Mass market:** Phosphagenics is in continuing discussions with a global & U.S. personal care companies for use of TPM® in skincare products with high volume sales.
Phosphagenics’ own brands (Elixia®/BioElixia™) and partner brands (Le Metier de Beaute™) use TPM’s® unique delivery system for better delivery of actives in a range of anti-wrinkle and anti-cellulite products.

BodyShaper® - our revolutionary anti-cellulite product
Objective photogrammetric testing showed an average reduction in the appearance of cellulite of over 37% after 4 weeks daily use and over 57% after 8 weeks daily use.
Value Drivers

• **TPM® Technology is a first in class platform delivery system**
  – Multiple revenue opportunities exist across diverse markets
  – All opportunities underpin growth in supply and manufacture of TPM®

• **Pharmaceutical Division**
  – Progress with TPM/oxycodone clinical trials
  – License TPM/oxycodone patch during or following completion of Phase 3
  – Licensing of other products, ie TPM/diclofenac topical formulation

• **Personal Care Division**
  – Mass market opportunity to partner/license with global player a priority
  – ELIXIA® and BioElixia™ growth opportunities in Aus, Asia, USA and Europe
PHOSPHAGENICS

www.phosphagenics.com
New York office: (212) 745 1387
Melbourne office: +61 3 9565 1119